Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 6130725, 7 pages
https://doi.org/10.1155/2017/6130725
Research Article

Procalcitonin Impairs Liver Cell Viability and Function In Vitro: A Potential New Mechanism of Liver Dysfunction and Failure during Sepsis?

1Clinic for Anesthesiology and Intensive Care Medicine, University Hospital Rostock, Rostock, Germany
2Fraunhofer Institute for Cell Therapy and Immunology, EXIM, Rostock, Germany

Correspondence should be addressed to Martin Sauer; ed.kcotsor-inu@reuas.nitram

Received 12 November 2016; Revised 5 January 2017; Accepted 10 January 2017; Published 1 February 2017

Academic Editor: Anastasia Kotanidou

Copyright © 2017 Martin Sauer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Jacobi, “Pathophysiology of sepsis,” American Journal of Health-System Pharmacy, vol. 59, supplement 1, pp. S3–S8, 2002. View at Google Scholar
  2. J.-L. Vincent, D. R. Nelson, and M. D. Williams, “Is worsening multiple organ failure the cause of death in patients with severe sepsis?” Critical Care Medicine, vol. 39, no. 5, pp. 1050–1055, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Bakker, R. Grover, A. McLuckie et al., “Administration of the nitric oxide synthase inhibitor NG-methyl- L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002),” Critical Care Medicine, vol. 32, no. 1, pp. 1–12, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Szabo, L. Romics, and G. Frendl, “Liver in sepsis and systemic inflammatory response syndrome,” Clinics in Liver Disease, vol. 6, no. 4, pp. 1045–1066, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. J.-F. Dhainaut, N. Marin, A. Mignon, and C. Vinsonneau, “Hepatic response to sepsis: interaction between coagulation and inflammatory processes,” Critical Care Medicine, vol. 29, no. 7, pp. S42–S47, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Nesseler, Y. Launey, C. Aninat, F. Morel, Y. Mallédant, and P. Seguin, “Clinical review: the liver in sepsis,” Critical Care, vol. 16, no. 5, article 235, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Linscheid, D. Seboek, D. J. Schaer, H. Zulewski, U. Keller, and B. Müller, “Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes,” Critical Care Medicine, vol. 32, no. 8, pp. 1715–1721, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Oberhoffer, I. Stonans, S. Russwurm et al., “Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro,” The Journal of Laboratory and Clinical Medicine, vol. 134, no. 1, pp. 49–55, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Russwurm, I. Stonans, E. Stonane et al., “Procalcitonin and cgrp-1 mrna expression in various human tissues,” Shock, vol. 16, pp. 109–112, 2001. View at Google Scholar
  10. N. G. Morgenthaler, J. Struck, Y. Chancerelle et al., “Production of procalcitonin (PCT) in non-thyroidal tissue after LPS injection,” Hormone and Metabolic Research, vol. 35, no. 5, pp. 290–295, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. E. S. Nylen, K. T. Whang, R. H. Snider Jr., P. M. Steinwald, J. C. White, and K. L. Becker, “Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis,” Critical Care Medicine, vol. 26, no. 6, pp. 1001–1006, 1998. View at Publisher · View at Google Scholar · View at Scopus
  12. K. E. Wagner, J. M. Martinez, S. D. Vath et al., “Early immunoneutralization of calcitonin precursors attenuates the adverse physiologic response to sepsis in pigs,” Critical Care Medicine, vol. 30, no. 10, pp. 2313–2321, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. A. A. Dahaba and H. Metzler, “Procalcitonin's role in the sepsis cascade. Is procalcitonin a sepsis marker or mediator?” Minerva Anestesiologica, vol. 75, no. 7-8, pp. 447–452, 2009. View at Google Scholar · View at Scopus
  14. N.-M. Wagner, C. Van Aken, A. Butschkau et al., “Procalcitonin impairs endothelial cell function and viability,” Anesthesia & Analgesia, 2016. View at Publisher · View at Google Scholar
  15. M. Sauer, “The use of human hepatocytes to determine liver function and liver regeneration,” PCT/EP 2007/001047; DE/2006 102006005526, 2007.
  16. M. Sauer, C. Haubner, T. Mencke et al., “Impaired cell functions of hepatocytes incubated with plasma of septic patients,” Inflammation Research, vol. 61, no. 6, pp. 609–616, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. D. A. Scudiero, R. H. Shoemaker, K. D. Paull et al., “Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines,” Cancer Research, vol. 48, no. 17, pp. 4827–4833, 1988. View at Google Scholar · View at Scopus
  18. K. Lorentz, R. Klauke, and E. Schmidt, “Recommendation for the determination of the catalytic concentration of lactate dehydrogenase at 37 degrees c. Standardization committee of the german society for clinical chemistry, enzyme working group of the german society for clinical chemistry,” European Journal of Clinical Chemistry and Clinical Biochemistry, vol. 31, no. 12, pp. 897–899, 1993. View at Google Scholar
  19. N. Krasteva, T. Groth, F. Fey-Lamprecht, and G. Altankov, “The role of surface wettability on hepatocyte adhesive interactions and function,” Journal of Biomaterials Science, Polymer Edition, vol. 12, no. 6, pp. 613–627, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. J. H. Kelly and N. L. Sussman, “A fluorescent cell-based assay for cytochrome P-450 isozyme 1A2 induction and inhibition,” Journal of Biomolecular Screening, vol. 5, no. 4, pp. 249–253, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. U. Bolder, H.-T. Ton-Nu, C. D. Schteingart, E. Frick, and A. F. Hofmann, “Hepatocyte transport of bile acids and organic anions in endotoxemic rats: impaired uptake and secretion,” Gastroenterology, vol. 112, no. 1, pp. 214–225, 1997. View at Publisher · View at Google Scholar · View at Scopus
  22. R. H. Moseley, “Sepsis and cholestasis,” Clinics in Liver Disease, vol. 3, no. 3, pp. 465–475, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Kramer, B. Jordan, W. Druml, P. Bauer, and P. G. H. Metnitz, “Incidence and prognosis of early hepatic dysfunction in critically ill patients—A Prospective Multicenter Study,” Critical Care Medicine, vol. 35, no. 4, pp. 1099–1104, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Koskinas, I. P. Gomatos, D. G. Tiniakos et al., “Liver histology in ICU patients dying from sepsis: a clinico-pathological study,” World Journal of Gastroenterology, vol. 14, no. 9, pp. 1389–1393, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Meisner, “Update on procalcitonin measurements,” Annals of Laboratory Medicine, vol. 34, no. 4, pp. 263–273, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Regueira, P. M. Lepper, S. Brandt et al., “Hypoxia inducible factor-1α induction by tumour necrosis factor-α, but not by toll-like receptor agonists, modulates cellular respiration in cultured human hepatocytes,” Liver International, vol. 29, no. 10, pp. 1582–1592, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. M. A. El-Saadany, H. M. Rawel, J. Raila, M. S. El-Dashloty, and F. J. Schweigert, “Antioxidants modulate the IL-6 induced inhibition of negative acute-phase protein secretion in HepG2 cells,” Cell Biochemistry and Function, vol. 26, no. 1, pp. 95–101, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Nakai, H. Tanaka, K. Hanada et al., “Decreased expression of cytochromes P450 1A2, 2E1, and 3A4 and drug transporters Na+-taurocholate-cotransporting polypeptide, organic cation transporter 1, and organic anion-transporting peptide-C correlates with the progression of liver fibrosis in chronic hepatitis C patients,” Drug Metabolism and Disposition, vol. 36, no. 9, pp. 1786–1793, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Li, A. Jahan, and J. Y. L. Chiang, “Bile acids and cytokines inhibit the human cholesterol 7α-hydroxylase gene via the JNK/c-Jun pathway in human liver cells,” Hepatology, vol. 43, no. 6, pp. 1202–1210, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Sombetzki, N. Koslowski, S. Doss et al., “Biosensor for hepatocellular injury corresponds to experimental scoring of hepatosplenic schistosomiasis in mice,” BioMed Research International, vol. 2016, Article ID 1567254, 7 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Sauer, J. Altrichter, C. Haubner et al., “Bioartificial therapy of sepsis: changes of norepinephrine-dosage in patients and influence on dynamic and cell based liver tests during extracorporeal treatments,” BioMed Research International, vol. 2016, Article ID 7056492, 11 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  32. J. H. Kelly and G. J. Darlington, “Modulation of the liver specific phenotype in the human hepatoblastoma line Hep G2,” In Vitro Cellular & Developmental Biology, vol. 25, no. 2, pp. 217–222, 1989. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Modrianský, J. Ulrichová, P. Bachleda et al., “Human hepatocyte—a model for toxicological studies. Functional and biochemical characterization,” General Physiology and Biophysics, vol. 19, no. 2, pp. 223–235, 2000. View at Google Scholar · View at Scopus
  34. P. F. Dehn, C. M. White, D. E. Conners, G. Shipkey, and T. A. Cumbo, “Characterization of the human hepatocellular carcinoma (HEPG2) cell line as an in vitro model for cadmium toxicity studies,” In Vitro Cellular and Developmental Biology—Animal, vol. 40, no. 5, pp. 172–182, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. J. A. Rule, L. S. Hynan, N. Attar et al., “Procalcitonin identifies cell injury, not bacterial infection, in acute liver failure,” PLoS ONE, vol. 10, no. 9, Article ID e0138566, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Araujo, S. Q. Doi, C. E. Palant, E. S. Nylen, and K. L. Becker, “Procalcitonin induced cytotoxicity and apoptosis in mesangial cells: implications for septic renal injury,” Inflammation Research, vol. 62, no. 10, pp. 887–894, 2013. View at Publisher · View at Google Scholar · View at Scopus